Dementia is a common neuropsychological disorder with an increasing incidence. The most prevalent type of dementia is Alzheimer's disease. The underlying pathophysiological features of the cognitive decline are neurodegenerative processes, a cerebrovascular dysfunction and immunological alterations. The therapeutic approaches are still limited, although intensive research is being conducted with the aim of finding neuroprotective strategies. The widely accepted cholinesterase inhibitors and glutamate antagonists did not meet expectations of preventing disease progression, and research is therefore currently focusing on novel targets. Nonsteroidal anti-inflammatory drugs, secretase inhibitors and statins are promising drug candidates for the prevention and management of different forms of dementia. The kynurenine pathway has been associated with various neurodegenerative disorders and cerebrovascular diseases. This pathway is also closely related to neuroinflammatory processes and it has been implicated in the pathomechanisms of certain kinds of dementia. Targeting the kynurenine system may be of therapeutic value in the future.
Introduction
Dementia is an acquired cognitive decline, beyond what might be attributed to normal aging. It is a general term referring to a clinical syndrome of multiple cognitive deficits with several different underlying pathologies. The classification of the various dementia types may be based on genetic, pathological or clinical features. The prevalence and incidence data reveal an increasing tendency in parallel with the aging of the population. The overall prevalence of dementia is around 6-8% [De Deyn et al. 2011; De Ronchi et al. 2005; Mejia-Arango and Gutierrez, 2011] , with the most prevalent type being Alzheimer's disease (AD) [Nestor et al. 2004 ].
The main pathogenic mechanisms involved in the development of dementia are neurodegeneration and a cerebrovascular dysfunction, which have been recognized to be closely associated [Honjo et al. 2012; Iadecola, 2010; Iadecola and Gorelick, 2003; Liu and Zhang, 2012] .
There are a number of common features in the pathomechanisms of neurodegenerative processes, including mitochondrial disturbances [Karbowski and Neutzner, 2012; Szalardy et al. 2012] , neuroinflammation [Glass et al. 2010] , glutamate excitotoxicity [Lau and Tymianski, 2010] and oxidative stress [Gandhi and Abramov, 2012] . Excitotoxic damage to neuronal cells is caused by the overactivation of glutamate receptors, inhibition of which could therefore be a promising neuroprotective strategy. A valuable endogenous neuroprotective molecule is kynurenic acid (KYNA), a tryptophan (TRP) metabolite produced in the kynurenine pathway (KP), which exerts broad-spectrum endogenous excitatory amino acid receptor antagonistic properties [Birch et al. 1988; Kessler et al. 1989; Perkins and Stone, 1982] .
There is currently no definite cure for dementia syndromes, although intensive research is under way with a view to the development of novel therapeutic interventions that may be able to prevent or slow down the progression of the disease, thereby improving the quality of life of patients. The KP offers a valuable target for neuroprotective therapies.
Dementia aetiology and diagnosis
The diagnosis of the dementia syndrome is usually based on the Diagnostic and Statistical Manual of Mental Disorders fourth edition (DSM-IV) criteria [American Psychiatric Association, 2000; Feldman et al. 2008] .
The diagnostic criteria for dementia are the following:
(1) an acquired memory decline and a severe impairment in one or more cognitive domains, including gnosis, executive function, praxis and language; (2) cognitive impairments that interfere with work or social activities.
A number of brief cognitive tests are available for the assessment of the overall cognitive performance, the most widely used being the highly sensitive and specific Mini Mental State Examination [Folstein et al. 1975] , and the clock-drawing test [Shulman, 2000] . Other tests include the Montreal Cognitive Assessment [Nasreddine et al. 2005] , DemTect [Kalbe et al. 2004 ], the 7-Minute Screen [Solomon et al. 1998 ] and the Behavioural Neurology Assessment short form [Darvesh et al. 2005] , which are more accurate in cases of mild dementia. After recognition of a cognitive impairment, a detailed clinical evaluation, specific laboratory tests and structural neuroimaging may help to identify the aetiology [Feldman et al. 2008; Gauthier et al. 2012] . The most common types of dementia are AD and vascular dementia, but there are multiple other pathologies which may lead to a cognitive decline (Table 1) .
The hallmark neuropathological features of the most common dementia form, AD, are amyloid-β protein deposition in senile plaques and cerebral blood vessels, and tau deposition in the neurons forming neurofibrillary tangles. The other main form, vascular dementia, is defined as the common presence of cognitive decline and a cerebrovascular disorder. Recent findings provided evidence that cerebrovascular dysfunction and neurodegenerative processes are strongly associated during the development of dementia [Iadecola and Gorelick, 2003] . Vascular risk factors may accelerate amyloid-β production and deposition, thereby contributing to disease progression in AD. Likewise, amyloid deposition causes cerebral amyloid angiopathy, which results in a disturbed cerebral perfusion [Honjo et al. 2012; Thal et al. 2008] . Neuroimaging studies have demonstrated that a reduced cerebral blood flow can be associated with early stages of AD, and cerebral hypoperfusion may precede the clinical symptoms of dementia and contribute to the development of AD [Rombouts et al. 2005; Ruitenberg et al. 2005] . Cerebrovascular dysfunction may contribute markedly to the development of neurodegenerative processes. Other vascular dementia forms may develop as a result of the presence of vascular risk factors, such as atherosclerosis or small vessel disease, and in post-stroke cases [Battistin and Cagnin, 2010; Thal et al. 2012] .
Cognitive decline and dementia may present in several neurodegenerative disorders. Huntington's disease (HD) is a chronic progressive disorder of autosomal dominant inheritance, which involves characteristic motor disturbances and a remarkable cognitive decline. The genetic background of HD is the polyglutamine expansion of the huntingtin gene [Tan and Yu, 2012] but recent genetic studies on yeasts have implicated several other genes which may influence the neurotoxic process, including kynurenine-3-monooxygenase (KMO) [Giorgini et al. 2005; Tauber et al. 2011] The kynurenine pathway and the role of kynurenines in dementia
The kynurenine pathway The KP, the main route of TRP metabolism, is responsible for the breakdown of more than 90% of the TRP in the human brain [Wolf, 1974] . This metabolic cascade involves several neuroactive metabolites, collectively termed kynurenines [Lapin, 1978; Zadori et al. 2011a] . Kynurenines have been shown to play important roles in the regulation of neurotransmission and in immunological processes [Vécsei, 2005; Vécsei et al. 2013; Zadori et al. 2011a ]. Alterations in the KP have been implicated in the pathomechanism of cerebral ischaemia Stone et al. 2012] , migraine [Fejes et al. 2011; Pardutz et al. 2012; Tajti et al. 2011 Tajti et al. , 2012 , AIDS dementia complex (ADC) [Guillemin et al. 2005b ] and several neurodegenerative disorders, including AD [Guillemin and Brew, 2002; Plangar et al. 2011; Zadori et al. 2011a ].
The KP of the TRP catabolism comprises multiple enzymatic steps that result in the formation of the essential coenzymes nicotinamide adenine dinucleotide (NAD) and NAD phosphate [Beadle et al. 1947] (Figure 1 ). The rate-limiting step of this metabolic route is the enzymatic degradation of TRP by indoleamine 2,3-dioxygenase (IDO) or TRP 2,3-dioxygenase (TDO). The first stable intermediate in the KP is L-kynurenine (L-KYN), which can be converted in two different routes: either by the kynurenine aminotransferases (KATs) to form the neuroprotective KYNA, or in a sequence of enzymatic steps which lead to the production of NAD [Beadle et al. 1947 ]. The four subtypes of KATs identified so far are mainly localized in the astrocytes within the brain [Guidetti et al. 2007; Guillemin et al. 2001; Han et al. 2010; Okuno et al. 1991; Yu et al. 2006 ]. In the human brain, KYNA production can be attributed mainly to the activity of KAT II [Guidetti et al. 2007 ]. KYNA is a broad-spectrum endogenous inhibitor of ionotropic excitatory amino acid receptors [Perkins and Stone, 1982] and a noncompetitive inhibitor of the α7 nicotinic acetylcholine receptor [Hilmas et al. 2001] , and it was recently discovered that it may also be a ligand for the previously orphan G-protein-coupled receptor GPR35 [Wang et al. 2006 ].
In the other main branch of the KP, L-KYN serves as a substrate for KMO, resulting in the production of 3-hydroxy-kynurenine (3-HK) [Battie and Verity, 1981] . The continuing downstream metabolic cascade then produces the free radical generator 3-hydroxyanthranilic acid (3-HANA) and the N-methyl-D-aspartate (NMDA) receptor agonist quinolinic acid (QUIN) [Foster et al. 1986 ]. 3-HK and 3-HANA are potent free radical generators, while QUIN displays neurotoxic properties, not only through the production of free radicals, but also by NMDA-receptor agonism [De Carvalho et al. 1996; Stone and Perkins, 1981] .
The enzymes participating in the KP are differently distributed among the different cells in the central nervous system (CNS): the microglial cells harbour little KAT, and the astrocytes contain hardly any KMO. KYNA production can therefore be attributed mainly to astrocytes, while microglial cells are primarily responsible for the synthesis of QUIN [Espey et al. 1997; Guillemin et al. 2001; Lehrmann et al. 2001] .
Kynurenine pathway alterations in Alzheimer's disease
An increasing body of evidence supports the notion that alterations in the KP are involved in the pathogenesis of AD [Baran et al. 1999; Widner et al. 2000 ]. As long ago as 1998, Baran demonstrated that the levels of 3-OH-KYN and L-KYN were slightly decreased in the brain of patients with pathologically confirmed AD, while the level of KYNA exhibited a significant increase in the putamen and caudate nucleus. This elevation in KYNA correlated strongly with an increased KAT I enzyme activity [Baran et al. 1999] . As concerns the peripheral kynurenine metabolism, the KYNA levels in the serum, red blood cells and cerebrospinal fluid (CSF) of patients with AD were decreased, with no alterations in the serum KAT I or KAT II activity [Hartai et al. 2007; Heyes et al. 1992 ]. Moreover, an increased serum KYN/TRP ratio has been detected in patients with AD, indicating an enhanced IDO activity, which may be explained by the role of inflammatory processes in the pathogenesis of AD [Widner et al. 2000 ]. Conversely, an increased IDO activity was correlated with several immune markers in the serum of patients with AD [Widner et al. 
2000
]. Interestingly, an increased level of TRP degradation correlated with a reduced cognitive performance [Widner et al. 2000 ]. An increased QUIN and IDO immunoreactivity has been detected in the hippocampus of patients with AD [Guillemin et al. 2005a ], pointing to the role of QUIN in the neurodegenerative process. This concept was further supported by the observation that QUIN is colocalized with hyperphosphorylated tau in the AD cortex, and QUIN also proved to induce tau phosphorylation in in vitro studies [Rahman et al. 2009 ].
The kynurenine pathway in other conditions of cognitive decline ADC is a characteristic dementia syndrome associated with human immunodeficiency virus type 1 infection. The neurotoxic kynurenine metabolite QUIN has been demonstrated to be involved in the development of ADC. The significantly elevated levels of QUIN detected in the CSF of patients with ADC correlated with the cognitive deficits, while zidovudine therapy resulted in a decreased QUIN level in parallel with a clinical improvement. These data raised the possibility that the neurotoxic properties of this metabolite contribute to disease progression [Heyes et al. 1991a [Heyes et al. , 1991b Kaul et al. 2001 ]. Experimental data indicated that an elevated QUIN production reflected local macrophage activation in the CNS [Valle et al. 2004 ].
KP metabolites have been associated with postsurgical cognitive impairment and the alterations observed in this patient population additionally correlated with inflammatory markers [Forrest et al. 2011 ]. An enhanced kynurenine metabolism has been demonstrated to correlate with the infarct volume and mortality in patients with stroke, and recent data suggested that an increased IDO activity resulting in a higher kynurenine/TRP ratio is associated with poststroke cognitive impairment [Darlington et al. 2007; Gold et al. 2011 ]. Other studies have implicated kynurenine metabolites in vascular cognitive impairment and other neuropsychiatric conditions [Oxenkrug, 2007] .
Experimental data indicate a correlation between KP alterations and HD pathomechanism. In early stages of HD, increased levels of QUIN and 3-OH-KYN have been measured [Guidetti et al. 2004 ]. Beal and colleagues demonstrated that KYNA levels are decreased in the striatum of HD patients [Beal et al. 1990] . Similarly, reduced KAT activity has been demonstrated in several brain regions of patients with HD [Jauch et al. 1995] . The results of a clinical study revealed an increased IDO and a decreased KAT activity, in parallel with an elevated level of oxidative stress [Stoy et al. 2005 ]. These alterations have been assumed to contribute to disease development. Similar changes in KAT activity have been observed in an animal model of HD [Csillik et al. 2002] . Another animal study provided evidence of an increased vulnerability to the neurotoxicity of QUIN after KAT deletion, while elevation of the KYNA concentration proved to be protective [Harris et al. 1998; Sapko et al. 2006 ].
Future therapeutic possibilities by targeting the kynurenine pathway
The roles of the above-mentioned alterations in patients with AD are still under investigation; the most feasible concept is that an accelerated kynurenine metabolism contributes to the neurodegenerative process through the overproduction of neurotoxic metabolites.
KYNA displays neuroprotective properties, but at concentrations above physiological it can exert adverse effects. The intracerebroventricular administration of KYNA resulted in behavioural abnormalities in rats, including stereotypy and ataxia [Vécsei and Beal, 1990] , and in another study KYNA level elevations caused spatial working memory deficits [Chess et al. 2007 ]. By contrast, one animal study demonstrated that the inhibition of KYNA formation may be associated with enhanced cognitive performance ]. However, under the pathological conditions in neurodegenerative processes in which glutamatergic excitotoxicity is present, inhibition of the overactivated glutamate receptors may restore the normal level of activation and improve the cognitive function. From this perspective, KYNA analogues may be a promising therapeutic tool in different pathologies relating to cognitive impairment, by exerting a neuroprotective effect and restoring normal glutamatergic neurotransmission.
KYNA itself can cross the blood-brain barrier only poorly [Fukui et al. 1991] , and its systemic administration as a therapeutic tool is therefore not feasible. Furthermore, it is rapidly excreted from the brain by organic acid transporters [Bahn et al. 2005] . One therapeutic possibility would be the administration of L-KYN together with probenecid, an organic acid transporter inhibitor; this concept has already been tested under ischaemic conditions with good results [Gigler et al. 2007; Robotka et al. 2008] . Another possibility could be the administration of the halogenated L-KYN derivative 4-chlorokynurenine, which produces the KYNA analogue 7-chlorokynurenic acid. 4-Chlorokynurenine has already successfully completed a phase I clinical safety trial (for further information, see the press release on the Vista Gen website/Press releases: http://www.vistagen.com/?p=1061) [Vécsei et al. 2013] . Other synthetic KYNA analogues have proved to be neuroprotective in different animal experiments, including HD, and recent data provided evidence that this novel KYNA-amide does not exert cognitive side effects [Gellert et al. 2012; Knyihar-Csillik et al. 2008; Vamos et al. 2010; Zadori et al. 2011b ]. Another approach could be the use of KMO inhibitors, which may shift the kynurenine metabolism towards KYNA production. KMO inhibition has been demonstrated to increase the brain KYNA concentration, improve spatial memory and anxiety deficits and prevent synaptic loss in a transgenic mouse model of AD [Zwilling et al. 2011 ]. The same compound tested in an HD animal model was able to slow down neurodegeneration and increase survival time [Zwilling et al. 2011 ]. Inhibition of KMO and TDO resulted in a shift of the KP towards KYNA formation and additionally ameliorated the neurodegenerative process in other animal models [Campesan et al. 2011 ].
Other possible novel therapeutic approaches in dementia
The therapies currently available for AD have the aim of restoring the cholinergic and glutamatergic dysfunction; cholinesterase inhibitors and the glutamate antagonist memantine are well known and widely used drugs. However, for other dementia types, the recommendations are not so clear. The evidence supports the use of cholinesterase inhibitors and memantine in Lewy body disease and Parkinson's disease dementia, with particular concern for side effects. For other dementia types, there is currently no robust evidence in favour of any pharmacological approach [Sorbi et al. 2012 ]. Intensive research is currently being carried out with a view to the development of novel therapeutic tools which could possibly slow disease progression besides providing symptomatic relief (Table 2) [Potter, 2010] .
Neuroinflammation is considered to be an important aspect in the pathomechanism of AD, and the observation from epidemiologic studies that nonsteroidal anti-inflammatory drugs (NSAIDs) were associated with a lower risk of AD gave rise to the concept of using anti-inflammatory drugs for the treatment of dementia [Szekely et al. 2004] . In vitro studies yielded evidence that some NSAIDs were able to decrease the level of the amyloid-β-42 peptide in cultured cells [Weggen et al. 2001] , while ibuprofen treatment in an animal model of AD resulted in a reduction of the amyloid plaque load and microglial activation [Yan et al. 2003 ]. Unfortunately, clinical trials have so far been disappointing [Aisen, 2002] . However, recently published data have suggested that selective cyclooxygenase 1 inhibitors may be of therapeutic value in AD, but further studies are needed to assess their efficacy [Choi et al. 2013] .
Lipid metabolism was linked with AD when the apolipoprotein E (ApoE) allele 4 was identified as a major genetic risk factor for AD [Corder et al. 1993 ]. ApoE is a major cholesterol transport protein in the brain [Mahley, 1988] . The ApoE ε allele has been associated with an increased risk of cerebral amyloid angiopathy [Greenberg et al. 1995] and HIV disease progression [Burt et al. 2008] , among others. ApoE, cholesterol and lipid metabolism alterations have been implicated in various stages of the pathogenesis of AD, including amyloid-β protein production and clearance, and cerebrovascular effects [Marzolo and Bu, 2009; Zlokovic, 2013] .
Statins have been associated with a lower risk of AD in large epidemiological studies [Wolozin et al. 2000 ]. This can be explained in part by the fact that hyperlipidaemia is one of the major vascular risk factors and cerebrovascular dysfunction may [Potter, 2010] .
Cholinergic receptor agonists
Vaccines against amyloid β Antibodies against amyloid β Secretase inhibitors Anti-inflammatory drugs tau-targeting agents contribute to the development of AD. Moreover, statins have been reported to decrease amyloid-β peptide production in a cholesterol-independent mechanism [Hosaka et al. 2013 ].
The amyloid-β protein is produced from amyloid precursor protein as a result of the proteolytic activity of β-secretase β-site APP cleavage enzyme 1 (BACE1) and the γ-secretase complex [Vassar, 2004] . Inhibition of BACE1 has been demonstrated to result in a lower amyloid-β protein level and to enhance cognitive impairment in an animal model of AD [Ohno et al. 2004] ; BACE1 inhibitors may therefore be of therapeutic value in patients with AD. The development of an orally available brainpenetrant BACE1 inhibitor was recently reported, which resulted in a reduced level of amyloid-β protein formation in rats [Stamford et al. 2012] , while another recently developed BACE1 inhibitor has already progressed to a phase I clinical trial [Jeppsson et al. 2012 ].
Conclusion
The pathomechanisms of different types of dementias are still under investigation, and the therapeutic possibilities are therefore limited. Neuroinflammatory processes, lipid metabolism and secretase inhibitors are currently controversial fields in drug development, but further research may facilitate an understanding. Alterations in the KP are common features in the neurodegenerative, cerebrovascular and immunological aspects of dementias. This may therefore lead to a promising novel therapeutic approach for all types of dementia. Corder, E., Saunders, A., Strittmatter, W., Schmechel, D., Gaskell, P., Small, G. et al. (1993) Gene dose of apolipoprotein E type 4 allele and the Guillemin, G. and Brew, B. (2002) Implications of the kynurenine pathway and quinolinic acid in Alzheimer's disease. Redox Rep 7: 199-206.
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